Oral drug combination eases treatment burden for AML patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 21:15 ET (23-Jun-2026 01:15 GMT/UTC)
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. In the international phase 1/phase 2 trial led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, Yale University and MD Anderson Cancer Center, patients took a regimen of two pills, decitabine-cedazuridine and venetoclax, with strong response rates and survival outcomes.
The United States Patent and Trademark Office (USPTO) officially issued a new patent to Wayne State University and RediMinds Inc. of Southfield, Michigan. The patent protects a pioneering technological advancement developed in the university's laboratories.